Dronabinol and marijuana in HIV+ marijuana smokers: acute effects on caloric intake and mood
- 804 Downloads
No studies to date have directly compared the tolerability and efficacy of smoked marijuana and oral dronabinol in HIV+ marijuana smokers.
The aim of this study was to compare dronabinol (0, 10, 20, 30 mg p.o.) and marijuana [0.0, 1.8, 2.8, 3.9% Δ9-tetrahydrocannabinol (THC)] in two samples of HIV+ marijuana smokers: those with (n=15) and those without (n=15) a clinically significant loss of muscle mass (<90% body cell mass/height), which is one component of AIDS wasting.
Mood, physical symptoms, self-selected food intake, cardiovascular data, and cognitive task performance were measured before and repeatedly after dronabinol and marijuana administration in eight 7-h sessions. Marijuana and dronabinol were administered in randomized order using a within-subject, staggered, double-dummy design.
As compared to placebo, (1) marijuana (1.8, 2.8, 3.9% THC) and the lower dronabinol doses (10, 20 mg) were well tolerated (e.g., few physical symptoms, significant increases in ratings of “good drug effect”) in both groups of participants; the highest dose of dronabinol (30 mg) was poorly tolerated in a subset of participants; (2) marijuana and dronabinol significantly increased caloric intake in the low bioelectrical impedance analysis (BIA) group but not in the normal BIA group; and (3) drug effects on cognitive performance were minor.
These data suggest that for experienced marijuana smokers with clinically significant muscle mass loss, both dronabinol (at acute doses at least four to eight times the current recommendation) and marijuana produce substantial and comparable increases in food intake without producing adverse effects.
KeywordsCannabinoids AIDS THC Appetite
We are grateful to Mabel Torres, Stephanie Wexelbaum, Cassidy Cleavinger, Martin McElhiney, Ph.D., Judy Chiu, and Carl Hart, Ph.D., for their excellent assistance in completing this research. We also thank the US National Institute on Drug Abuse and the National Center for Complementary and Alternative Medicine (DA 09236 and DA12698) for their support and for providing study marijuana.
- Abrams DI, Hilton JF, Leiser RJ, Shade SB, Elbeik TA, Aweeka FT, Benowitz NL, Bredt BM, Kosel B, Aberg JA, Deeks SG, Mitchell TF, Mulligan K, Bacchetti P, McCune JM, Schambelan M (2003) Short-term effects of cannabinoids in patients with HIV-1 infection. Ann Intern Med 139:258–266PubMedGoogle Scholar
- Beal JE, Olson R, Lefkowitz L, Laubenstein L, Bellman P, Yangco B, Morales JO, Murphy R, Powderly W, Plasse TF, Mosdell KW, Shepard KV (1997) Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. J Pain Symptom Manage 14:7–14PubMedCrossRefGoogle Scholar
- Grinspoon L, Bakalar J (1993) Marihuana, the forbidden medicine. Yale University Press, New HavenGoogle Scholar
- Heatherington M, Rolls BJ (1987) Methods of investigating human eating behavior. In: Toates F, Rowland N (eds) Feeding and drinking. Elsevier, Amsterdam, pp 77–109Google Scholar
- Institute of Medicine (1999) Marijuana and medicine: assessing the science base. National Academy Press, Washington, DCGoogle Scholar
- Palenicek JP, Graham NMH, He YD, Hoover DA, Oishi JS, Kingsley L, Saah AJ (1995) Weight loss prior to clinical AIDS as a predictor of survival. Multicenter AIDS Cohort Study Investigators. J Acquir Immune Defic Syndr 10:366–373Google Scholar
- Polen MR, Sidney S, Tekawa IS, Sadler M, Friedman GD (1993) Health care use by frequent marijuana smokers who do not smoke tobacco. Western J Med 158:596–601Google Scholar
- Tashkin DP (1999) Marihuana and the lung. In: Nahas GG, Pace N, Cancro R (eds) Marihuana and medicine. Humana Press, Totowa, NJ, pp 279–287Google Scholar
- Timpone JG, Wright DJ, Li N, Egorin MJ, Enama ME, Mayers J, Galetto G (1997) The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronobinol for the treatment of HIV wasting syndrome. The DATRI 004 Study Group. Division of AIDS Treatment Research Initiative. AIDS Res Hum Retroviruses 13:305–315PubMedCrossRefGoogle Scholar